Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool

Cancer Commun (Lond). 2022 Oct;42(10):1028-1031. doi: 10.1002/cac2.12335. Epub 2022 Jul 18.

Authors

Nicolas A Fraunhoffer^{1

2}, Analía Meilerman Abuelafia¹, Nelson Dusetti¹, Juan Iovanna¹

Affiliations

¹ Cancer Research Center of Marseille, Inserm, Paoli-Calmettes Institut, Aix-Marseille University, Scientific and Technological Park of Luminy, Marseille, 13288, France.
² Buenos Aires University, Center for Pharmacological and Botanical Studies, Faculty of Medicine, National Council for Scientific and Technical Research, Buenos Aires, C1121ABG, Argentina.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Organoids*
Pancreatic Neoplasms* / drug therapy

Associated data

ClinicalTrials.gov/NCT01692873